These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33580098)

  • 1. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
    Parvathareddy SK; Siraj AK; Al-Badawi IA; Tulbah A; Al-Dayel F; Al-Kuraya KS
    Sci Rep; 2021 Feb; 11(1):3750. PubMed ID: 33580098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
    Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
    Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
    Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
    Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
    Zhu X; Yang H; Lang J; Zhang Y
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
    Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
    Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    Zhu J; Wen H; Ju X; Bi R; Zuo W; Wu X
    PLoS One; 2017; 12(1):e0170879. PubMed ID: 28125702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
    Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.
    Nikas IP; Lee C; Song MJ; Kim B; Ryu HS
    Cancer Med; 2022 Jun; 11(11):2193-2203. PubMed ID: 35212471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
    Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
    BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
    Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
    Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
    Udager AM; Liu TY; Skala SL; Magers MJ; McDaniel AS; Spratt DE; Feng FY; Siddiqui J; Cao X; Fields KL; Morgan TM; Palapattu GS; Weizer AZ; Chinnaiyan AM; Alva A; Montgomery JS; Tomlins SA; Jiang H; Mehra R
    Ann Oncol; 2016 Sep; 27(9):1706-12. PubMed ID: 27217541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
    Han GH; Hwang I; Cho H; Ylaya K; Choi JA; Kwon H; Chung JY; Hewitt SM; Kim JH
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.